S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 Reasons This Tech Giant Is Going Back To Highs
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
OTCMKTS:UCBJF

UCB (UCBJF) Stock Forecast, Price & News

$89.30
0.00 (0.00%)
(As of 09/20/2023 ET)
Compare
Today's Range
$89.27
$89.52
50-Day Range
$86.29
$89.91
52-Week Range
$68.30
$98.29
Volume
23 shs
Average Volume
107 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00

UCB MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
34.4% Upside
$120.00 Price Target
Short Interest
Bearish
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
31.90%
From $3.95 to $5.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars


UCBJF stock logo

About UCB (OTCMKTS:UCBJF) Stock

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCBJF Price History

UCBJF Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
UCB SA (UCBJF)
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
ZGNX Jan 2022 7.000 call
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Why New Oriental Education Shares Are Falling
SpectrumDNA, Inc. (SPXA)
UCB unleashes the power of data in new collaboration
UCB boosts gene therapy footprint with two new deals
See More Headlines
Receive UCBJF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter.

UCBJF Company Calendar

Today
9/20/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:UCBJF
Employees
8,703
Year Founded
1928

Price Target and Rating

Average Stock Price Forecast
$105.00
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$105.00
Forecasted Upside/Downside
+34.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.81 billion
Cash Flow
$7.90 per share
Book Value
$50.52 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.50

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Jean-Christophe Tellier (Age 64)
    CEO & Exec. Director
    Comp: $3.57M
  • Ms. Sandrine Dufour CFA (Age 57)
    Exec. VP & CFO & Chief Corp. Devel.
  • Ms. Kirsten Lund-Jurgensen (Age 64)
    Exec. VP of Supply & Technology Solutions
  • Dr. Dhavalkumar D. Patel M.D. (Age 62)
    Ph.D., Exec. VP & Chief Scientific Officer
  • Mr. Jean-Luc Fleurial (Age 58)
    Exec. VP & Chief HR Officer
  • Prof. Iris Low-Friedrich (Age 63)
    Exec. VP, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices
  • Mr. Emmanuel Caeymaex (Age 54)
    Exec. VP of Immunology Solutions & Head of US
  • Ms. Caroline Vancoillie
    Chief Accounting Officer, Head of Group Fin. & CFO of Patient Value Functions
  • Antje Witte
    Head of Investor Relations
  • Ms. Denelle J. Waynick Johnson J.D.
    Exec. VP & Gen. Counsel













UCBJF Stock - Frequently Asked Questions

Should I buy or sell UCB stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UCBJF shares.
View UCBJF analyst ratings
or view top-rated stocks.

What is UCB's stock price forecast for 2023?

6 brokers have issued 12 month target prices for UCB's shares. Their UCBJF share price forecasts range from $105.00 to $105.00. On average, they predict the company's stock price to reach $105.00 in the next year. This suggests a possible upside of 17.6% from the stock's current price.
View analysts price targets for UCBJF
or view top-rated stocks among Wall Street analysts.

How have UCBJF shares performed in 2023?

UCB's stock was trading at $80.40 at the beginning of 2023. Since then, UCBJF shares have increased by 11.1% and is now trading at $89.30.
View the best growth stocks for 2023 here
.

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

How do I buy shares of UCB?

Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $89.30.

How many employees does UCB have?

The company employs 8,703 workers across the globe.

How can I contact UCB?

UCB's mailing address is Allee de la Recherche 60, Brussels C9, 1070. The official website for the company is www.ucb.com. The company can be reached via phone at (322) 559-9999, via email at investor-relations@ucb.com, or via fax at 32-2559-9900.

This page (OTCMKTS:UCBJF) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -